Multi-disciplinary Care for Brain Metastases
Part of paid clinical trials in Burlington, Vermont.
- Sponsor
- University of Vermont Medical Center
- Study ID
- NCT06280300
- Status
- Recruiting
Conditions
- Brain Metastases, Adult
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- health services intervention — OTHERHealth services intervention
Study Details
This is a health services intervention study aimed at understanding the impact of intensive multi-disciplinary care compared with standard care on patient-reported symptom outcomes and prognostic awareness in patients with brain metastases.
Key Dates
- Start date
- Nov 16, 2023
- Status verified
- Dec 2025
- Primary completion
- Dec 31, 2026
- Completion
- Jul 1, 2027
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Active Comparator: Standard of Care
- Experimental: Multidisciplinary Care
Primary Outcome Measure
Patient reported outcomes [ Time Frame: 6-12 months ]
Central Contacts
- Alissa A Thomas, MD802-847-8400
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Vermont Medical Center | Burlington | Vermont | 05401 | - |
Find similar trials in Burlington, VT
By research site
Related Studies
- Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic TrialPHASE2 · Recruiting · University of Vermont Medical Center · Burlington, Vermont
- UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain MetastasesPHASE2 · Recruiting · Jona Hattangadi-Gluth · San Diego, California
- Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic RadiosurgeryPHASE1 · Recruiting · Baptist Health South Florida · Miami, Florida
- Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain MetastasesPHASE1/PHASE2 · Recruiting · Colette Shen · Birmingham, Alabama